MedAlliance

What MedAlliance does

MedAlliance is a privately-held medical technology company headquartered in Nyon, Switzerland. Founded in 2008, the company operates as a for-profit private enterprise with 51-100 employees. The company is positioned in the European medical technology sector, with its Swiss domicile providing access to established medtech infrastructure and CE marking regulatory pathways. Specific product portfolio, pipeline, and indication details are not disclosed in the available source material.

The company has attracted significant institutional capital, raising $50 million in a Series 4 funding round on March 17, 2021, led by CITIC Capital Holdings with participation from Trustar Capital. This capital raise reflects institutional confidence in MedAlliance's commercial prospects. The company has also pursued inorganic growth, completing the acquisition of MDK Medical on February 3, 2022, for an undisclosed amount, suggesting a strategic consolidation or capability-expansion play within the medtech sector. The combination of institutional capital, M&A activity, and an established C-suite indicates the company is in an active scaling phase.

MedAlliance is led by Jeffrey B. Jump, who serves as Chairman and CEO, with Joseph Shultz as Chief Technology Officer and Scott Addonizio as Chief Operating Officer. The company operates as a private entity without disclosed public listing plans. The absence of detailed product, customer, revenue, and competitive positioning data in the source material limits deeper commercial assessment, but the available signals (institutional backing, M&A activity, mid-sized headcount) suggest an established mid-market medtech firm pursuing growth.

Name

MedAlliance

Legal name

Knowledge

Website

https://medalliance.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

51–100 employees

Short description

MedAlliance is a privately-held Swiss medical technology company founded in 2008 and headquartered in Nyon. Backed by CITIC Capital and Trustar Capital, the firm pursues growth through acquisitions in the medtech sector.

Ownership category

akta.pro rank

Headquarters

HQ city

Nyon

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. Professional Services and Consulting: Knowledge operates as an intelligent processes consultancy, generating revenue through custom software development, AI integration projects, data analytics consulting, and structural consulting services. Projects are delivered using iterative sprint methodologies with functional prototypes, suggesting project-based engagement rather than recurring subscriptions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

MedAlliance is a privately-owned medical technology company founded in 2008 and headquartered in Nyon, Switzerland, operating with 51–100 employees. Beyond its classification as a medical technology business and its growth-stage investor backing, the supplied source material does not detail specific commercial products, services, or therapeutic areas; the only explicitly disclosed business events are a $50 million financing round (March 2021, led by CITIC Capital Holdings with Trustar Capital) and the acquisition of MDK Medical (February 2022).

Product overview

Knowledge Intelligent Processes (Knowledge) operates as a technology consulting firm offering a portfolio of digital solutions centered around web/mobile development, AI integration, data analytics, and structural consulting services. The core offerings include custom web and mobile application development, AI-powered automation solutions (bots, assistants, recommendations), data analysis and visualization (dashboards, demand forecasting), and structural business consulting. The product portfolio is delivered through an agile methodology using systems thinking, with iterative sprints producing functional prototypes that evolve through real-world testing and feedback. The company serves multiple sectors including healthcare (pre-hospital care, medical records digitization), transportation (route optimization), and general business operations.

Differentiator

Problem solved

Functional benefit

Products and services

• Medical devices and related medical technology products (specific product names not disclosed in source)

Quantifiable outcome

• Reduction in registration errors and improved response times through digitalized pre-hospital care operations
• +6 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature5 records

Scale indicators1 record

Recent moves3 records

Expansion highlights3 records

Direct peers

• Boston Scientific: Boston Scientific is a global interventional cardiology and peripheral vascular incumbent with the Ranger and Eluvia drug-coated/drug-eluting platforms, directly competing with MedAlliance in the DCB category across coronary and peripheral indications.
• Medtronic: Medtronic markets the IN.PACT Admiral and IN.PACT AV drug-coated balloons for peripheral and AV access indications, making it a directly comparable DCB competitor with global commercial reach.
• BD (Bard): BD's Peripheral Intervention business sells the Lutonix drug-coated balloon for superficial femoral artery and below-the-knee lesions, directly overlapping MedAlliance's peripheral vascular indication footprint.
• Abbott: Abbott competes in the interventional vascular space with bioresorbable scaffolds, drug-eluting stents, and balloon technologies, providing overlapping solutions for the same physician call points as MedAlliance.
• B. Braun: B. Braun's Aesculap division markets the SeQuent Please neo paclitaxel-coated balloon, a directly competitive coronary and peripheral DCB that competes for the same procedural share as MedAlliance's sirolimus platform.
• Terumo: Terumo's interventional systems division sells drug-eluting balloons and stents for coronary and peripheral applications, competing head-to-head with MedAlliance in Asian and European markets.

Emerging players

• Concept Medical: Concept Medical is an emerging DCB specialist with the MagicTouch sirolimus-coated balloon, competing directly with MedAlliance's sirolimus technology in coronary and peripheral vascular indications.
• SurModics: SurModics is a smaller specialty player focused on drug-delivery coating technology used in DCBs and other vascular devices, providing adjacent technology competition to MedAlliance's proprietary sirolimus coating.
• Shockwave Medical: Shockwave Medical pioneered intravascular lithotripsy as an alternative to DCB and stenting for calcified lesions, representing an emerging adjacent technology competing for the same vascular interventional procedures.

Broad incumbents

• Cordis: Cordis is a global cardiovascular interventional device incumbent with a broad portfolio across coronary and peripheral vascular, positioning it as a strategic acquirer and broad competitor in the same procedural categories as MedAlliance.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key highlights6 records

Customer concentration

• Xx.com/MedallianceSA

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MedAlliance